Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020


The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies

Publication date
September 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest preclinical agreements announced in the healthcare sector.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


This report contains a comprehensive listing of over 1,800 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner preclinical stage compounds/products.


Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.


Chapter 5 provides a review of preclinical stage deal making since 2014. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.


Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.


Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 


Chapter 8 provides a comprehensive listing of the top 25 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 


Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2014, where a contract document is available in the public domain.


Chapter 10 provides a comprehensive directory of preclinical stage partnering deals since 2014.


The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.


The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2014.


In addition, a comprehensive appendix of all preclinical deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.


Key benefits


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of preclinical stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of preclinical stage agreements with numerous real life case studies
  • Insight into the terms included in a preclinical stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.


Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 includes:


  • Trends in preclinical stage dealmaking in the biopharma industry since 2014
  • Analysis of preclinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life preclinical stage deals
  • Access to over 1,800 preclinical stage deals
  • The leading preclinical stage deals by value since 2014
  • Most active preclinical stage dealmakers since 2014
  • The leading preclinical stage partnering resources


In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020, the available contracts are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,800 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides the reader with the following key benefits:


  • In-depth understanding of preclinical stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 1,800 preclinical stage deals together with contract documents if available
  • Detailed access to actual preclinical stage deals entered into by the leading big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of preclinical stage agreements with numerous real life case studies
  • Identify leading preclinical stage deals by value since 2014
  • Identify the most active preclinical stage dealmakers since 2014
  • Full listing of preclinical stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Why do companies partner preclinical stage compounds?           


2.1. Introduction

2.2. The role of preclinical stage partnering

2.2.1. In-licensing at preclinical stage

2.2.2. Out-licensing at preclinical stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into preclinical stage partnering deals

2.4.1. Licensors reasons for entering preclinical stage deals

2.4.2. Licensees reasons for entering preclinical stage deals

2.5. The future of preclinical stage partnering deals


Chapter 3 – Preclinical stage deal strategies and structure


3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical / biotech Discovery and preclinical stage partnering case studies Case study: LEO Pharma - 4SC Case study: Heptares Therapeutics - Cubist Case study: Incyte – Agenus Bio Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech Clinical stage partnering case studies Case study: Servier – GeNeuro Case study: Teva – Xenon Pharmaceuticals Case study: AstraZeneca - Ardelyx Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on preclinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure preclinical stage licensing agreements

3.6.1.a. Case study : Merck and Co. – Tesaro

3.6.1.b. Case study : Marina Biotech – Mirna Therapeutics

3.7. Multicomponent preclinical stage partnering agreements

3.7.1. Example multicomponent preclinical stage clauses

3.7.1.a. Case study: Eleven Biotherapeutics – ThromboGenics

3.7.1.b. Case study: Pfizer – InSite Vision


Chapter 4 – Preclinical stage partnering payment strategies


4.1. Introduction

4.2. Preclinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments Issues affecting royalty rates Royalties on combination products Case study: Scripps Research Institute-Cyanotech Guaranteed minimum/maximum annual payments Royalty stacking Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments


Chapter 5 – Trends in preclinical stage deal making


5.1. Introduction

5.2. Preclinical stage partnering over the years

5.2.1. Attributes of preclinical deals

5.3. Preclinical stage partnering by deal type

5.4. Preclinical stage partnering by disease type

5.5. Partnering by preclinical stage technology type

5.6. Preclinical stage partnering by most active company since 2014


Chapter 6 – Payment terms for preclinical stage partnering


6.1. Introduction

6.2. Guidelines for preclinical stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Preclinical stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Preclinical stage headline values

6.4.2. Preclinical stage deal upfront payments

6.4.3. Preclinical stage deal milestone payments

6.4.4. Preclinical stage royalty rates


Chapter 7 – Leading preclinical stage deals


7.1. Introduction

7.2. Top preclinical stage deals by value


Chapter 8 – Top 25 most active preclinical stage dealmakers


8.1. Introduction

8.2. Top 25 most active preclinical stage dealmakers


Chapter 9 – Preclinical stage partnering contracts directory


9.1. Introduction

9.2. Preclinical stage deals with contracts 2014 to 2020


Chapter 10 – Preclinical stage deal making by development stage


10.1. Introduction

10.2. Deals by preclinical stage




Appendix 1 – Preclinical stage dealmaking by companies A-Z

Appendix 2 – Preclinical stage dealmaking by industry sector

Appendix 3 – Preclinical stage dealmaking by stage of development

Appendix 4 – Preclinical stage dealmaking by therapy area

Appendix 5 – Preclinical stage dealmaking by technology type


About Wildwood Ventures


Current Partnering

Current Agreements

Recent titles from Current Partnering


Table of figures


Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for preclinical stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Preclinical stage partnering frequency 2014 - 2020
Figure 6: Preclinical stage partnering by deal type since 2014
Figure 7: Preclinical stage partnering by disease type since 2014
Figure 8: Preclinical stage partnering by technology type since 2014
Figure 9: Top 25 most active preclinical stage dealmakers, 2014 to 2020
Figure 10: Review of upfront payments for preclinical stage deals
Figure 11: Review of milestone payments for preclinical stage deals
Figure 12: Review of royalty payments for preclinical stage deals
Figure 13: Preclinical stage deals with a headline value
Figure 14: Preclinical stage deals with an upfront value
Figure 15: Preclinical stage deals with a milestone value
Figure 16: Preclinical stage deals with a royalty rate value
Figure 17: Top preclinical stage deals by value since 2014
Figure 18: Most active preclinical stage dealmakers 2014 to 2020

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2A, 3B Pharmaceuticals, 3DMed, 3SBio, 4D Molecular Therapeutics, 4SC, 23andMe, A*STAR Agency for Science, Technology and Research, AB-Biotics, AB Biosciences, Abbott Laboratories, Abbott Vascular Devices, Abbvie, AbClon, Ab E Discovery, Abeona Therapeutics, Abide Therapeutics, ABL Bio, Abpro, Abzena, Accelovance, AccuGenomics, Acetylon Pharmaceuticals, Achaogen, Achieve Life Science, AC Immune, Aclaris Therapeutics, ACT Biotech, Acticor Biotech, Actinium Pharmaceuticals, Acucela, AcuraStem, Acurx Pharmaceuticals, AdAlta, Adaptimmune, Adapt Pharma, ADC Therapeutics, Addex Therapeutics, Adimab, Aduro BioTech, Advaccine Biotechnology, Advaita, Advanced Accelerator Applications, Advanced BioScience Laboratories, Advaxis, Aerie Pharmaceuticals, Aevi Genomic Medicine, AffaMed Therapeutics, Affigen, Affinium Pharmaceuticals, Affinivax, AFFiRiS, AGC Biologics, Agenus Bio, Agilvax, Agios Pharmaceuticals, AgonOx, AGTC, AIMM Therapeutics, Aimmune Therapeutics, Ajinomoto, Akaal Pharma, Akcea Therapeutics, Akebia Therapeutics, Akero Therapeutics, Akeso Biopharma, AKESOgen, Akouos, Akoya Biosciences, Akston Biosciences, Albert Einstein College of Medicine, Alderley Analytical, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, Algenex, AliveGen, Alivio Therapeutics, Alkahest, Alkermes, Allergan, Alliance for Cancer Gene Therapy, Alligator Bioscience, Allogene Therapeutics, Alma Bio Therapeutics, Almirall, Alnylam Pharmaceuticals, Alphamab, Alpine Immune Sciences, ALS Association, ALS Biopharma, Altamira Pharma, Altasciences, Alteogen, ALTuCELL, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Alzheimers Research UK, Amarantus BioSciences, Ambrx, amcure, American Foundation for AIDS Research (amfAR), American National Multiple Sclerosis Society, Amgen, Amicus Therapeutics, Amneal Pharmaceuticals, AmorChem, Amorsa Therapeutics, AmpliPhi Biosciences, Amunix, Amylgen, Amyris, AnaBios, AnaptysBio, Anavex Life Sciences, AnGes MG, Angiex, Anika Therapeutics, Animal Life Sciences, Anixa Biosciences, Anokion, ANP Technologies, Antengene, Anterios, Anthos Therapeutics, Antidote Therapeutics, Antitope, Antoxerene, Apceth, Appello Pharmaceuticals, Appili Therapeutics, Applied BioMath, Applied Molecular Transport, Aprea, Aptahem, Aptar Pharma, Aptevo Therapeutics, Aptinyx, Aptose Biosciences, Aquinnah Pharmaceuticals, Aratana Therapeutics, Aravive Biologics, Arbutus, ArcherDX, Arcus Biosciences, Arcutis, Ardelyx, Ardena, Arecor, Arena Pharmaceuticals, arGEN-X, argenx, Argos Therapeutics, Ariad Pharmaceuticals, Aridis Pharmaceuticals, Arisaph Pharmaceuticals, Arix Bioscience, Arizona State University, Ark Biosciences, Arno Therapeutics (inactive since 2017), AroCell, Aromics, ArQule, Arrevus, Arrowhead Pharmaceuticals, Arrys Therapeutics, Arsanis Biosciences, Artelo Biosciences, Artios Pharma, Artizan Biosciences, Ascentage Pharma, AskAt, Asklepios Biopharmaceutical, Aslan Pharma, Aspen Park Pharmaceuticals, Assembly Biosciences, Astellas Pharma, Asterias Biotherapeutics, AstraZeneca, Atara Biotherapeutics, Atelerix, Athenex, Athersys, Auburn University, Audentes Therapeutics, AUM Biotech, Aurigene Discovery Technologies, AusHealth, Autifony Therapeutics, Avacta, Avalanche Biotechnologies, AVEO Oncology, AveXis, Avicanna, Avrobio, Axovant Sciences, Axxam, Ayala Pharmaceuticals, Aytu BioScience, Azaya Therapeutics, Azellon Cell Therapeutics, Bachem, Baergic Bio, Baker IDI Heart and Diabetes Institute, Batavia Biosciences, Bayer, Bayer Healthcare, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, BB100, Beacon Discovery, Beactica, BeiGene, Bellicum Pharmaceuticals, Ben-Gurion University, Benitec Biopharma, Berlin-Brandenburg Center for Regenerative Therapies, Beroni Group, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, BGI, BGN Technologies, Bill and Melinda Gates Foundation, BioAgilytix, BioArctic Neuroscience, biOasis Technologies, BioAtla, BioAxone Therapeutic, BioCancell Therapeutics, Biocept, Bioceros, BiocerOX Products, Biocon, BioCorRx, BioCryst Pharmaceuticals, BioCure, Biodesix, BioDuro, Biogen, Bioharmony Therapeutics, Biohaven Pharmaceutical Holding, BioIVT, Biokinetic Europe, BioLamina, BiolineRX, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), BioMed X Innovation Center, Biomica, BioMotiv, BiomX, BioNTech, Bionure, Biopharmaceuticals Australia, BioPharma Forest, Bioscience Pharma Partners, Biose Industrie, BioSig Technologies, BioSpring, Biostar Pharmaceuticals, Biothera, BioTheranostics, Biotheus, BioVaxys, Bioventus, Bioverativ, BioVersys, Biovista, BioWa, BioXcel, BirchBioMed, Bird Foundation, BJ Bioscience, Blackstone, Bloom Science, Bluebird Bio, Blueprint Medicines, Blue Water Vaccines, BlueWillow Biologics, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Boston Pharmaceuticals, Botanisol, BoyaLife, Bpifrance, BrainStorm Cell Therapeutics, Brickell Biotech, BridgeBio Pharma, Brigham and Women's Hospital, Brii Biosciences, Bristol-Myers Squibb, BryoLogyx, Buck Institute for Age Research, C-Bridge Capital, C2N Diagnostics, C4 Therapeutics, C4X Discovery, Cadent, Cadila Pharmaceuticals, Caladrius Biosciences, Calico, Calidi Biotherapeutics, California Institute for Biomedical Research, California Institute for Medical Researc, California Institute for Regenerative Medicine, Calithera Biosciences, Calvert Research, Calypso Biotech, Camargo Pharmaceutical Services, Camurus, Can-Fite BioPharma, CanBas, CANbridge Life Sciences, Cancer Prevention and Research Institute of Texas, Cancer Prevention Pharmaceuticals, Cancer Research Technology, Cancer Research UK, Cannabis Science, Cantargia, Capricor Therapeutics, CARB-X, Cardiff University, Cardium Therapeutics, Cardurion Pharmaceuticals, Caris Life Sciences, Carisma Therapeutics, Carna BioSciences, CARsgen, Cascadian Therapeutics, Case Western Reserve University, Castle Creek Pharmaceuticals, Catabasis Pharmaceuticals, Catalent, Catalyst Biosciences, CBT Pharmaceuticals, Cedars-Sinai Medical Center, Celgene, Cell and Gene Therapy Catapult, Cellectar Biosciences, Cellect Biotechnology, Cellectis, Cellectricon, Cellerant Therapeutics, Cell Medica, Cellmid, Cell Therapy Catapult, Celltrion, Cellular Biomedicine, Celmatix, Cel Sci, Celsion, Celularity, Celyad, Cenix BioScience, Censo Biotechnologies, Centers for Disease Control and Prevention, Centogene, Centre de Recherche en Cancérologie de Lyon, Centre for Commercialization of Regenerative Medicine (CCRM), Centre For The Commercialization Of Antibodies And Biologics, Centre Hospital University - Bordeaux, Centre National de Biologie Expérimentale, Centrexion, Cerebral Therapeutics, CereHealth, Certara, Certis, Cerveau Technologies, Cesca Therapeutics, Cevec Pharmaceuticals, cGMP Validation, Champions Oncology, Changchun BCHT Biotechnology, Changzhou Le Sun Pharmaceuticals, Charcot-Marie-Tooth Association, Charite-Universitatsmedizin, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chembio Diagnostics, Chemveda Life Sciences, Chiesi Farmaceutici, Children's Hospital Boston, Children's Hospital of Philadelphia, China Medical System, Chinook Therapeutics, Chongqing Lummy Pharma, ChromaDex, Chroma Therapeutics, Chromocell, Chronos Therapeutics, Chrysalis BioTherapeutics, Chugai Pharmaceutical, Ciclofilin Pharmaceuticals, Cilag AG, Cimtech, Cincinnati Children’s Hospital Medical Center, Cingulate Therapeutics (CTx), Cipher Pharmaceuticals, Circuit Therapeutics, Cisen Pharma, CiToxLAB, City of Hope, CiVi Biopharma, Clarity Pharmaceuticals, Claude Bourgelat Institute, Clene Nanomedicine, Cleveland Clinic, Clevexel Pharma, Click Therapeutics, Clinical Laserthermia Systems (CLS), Clinica Universidad Navarra, Clovis Oncology, CMAB Biopharma, CMC Biologics, CNS Pharmaceuticals, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cochin Hospital, Cochlear, Cocrystal Pharma, Codexis, Cofactor Genomics, Cognate BioServices, Colibri Heart Valve, College of Life Science of Northwest University, Columbia Technology Ventures, Columbia University, Colzyx, CombiGene, Compugen, Concept Life Sciences, Confo Therapeutics, Connecticut Innovations, Connexios, ConsortiaTX, Constance Therapeutics, ContraFect, ConverGene, Cook Biotech, Copernicus Therapeutics, Corbus Pharmaceuticals, Corden Pharma, CoreBiome, Coronado Biosciences, Cortexyme, Corvidia Therapeutics, Cosmo Bio, COTA, Covance, Crescendo Bioscience, Crestone Pharma, Croix-Rousse Hospital, Cronos Group, Crossbeta Biosciences, Crown Bioscience, Crozet BioPharma, CrystalGenomics, CSL, CSPC Pharmaceutical Group, CStone Pharmaceuticals, Cullinan Oncology, Cumulus Oncology, Curadev Pharma, Cure Duchenne, CureVac, Cureveda, Curie-Cancer, Curis, Cyclacel Pharmaceuticals, Cyclica, Cynata Therapeutics, Cypralis, Cystic Fibrosis Foundation, Cystic Fibrosis Foundation Therapeutics, Cyteir Therapeutics, Cytokinetics, CytomX Therapeutics, Cytos Biotechnology, Cytovant Sciences, Cyxone, D. Western Therapeutics Institute, Daiichi Sankyo, Dainippon Sumitomo Pharma, Dako, Dalhousie University, Dana-Farber Cancer Institute, DarwinHealth, Debiopharm, Decibel Therapeutics, DecImmune Therapeutics, de Duve Institute, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Defymed, Delphi Genetics, Denali Therapeutics, Denator, Dendreon, DendroCyte, Denovo Biopharma, Department of Defense, Department of Economic development of Montgomery County, Department of Health and Human Services, Department of Veterans Affairs, DePuy, Dermata Therapeutics, Dermelix Biotherapeutics, Dermira, DiagnoCure, Dianomi Therapeutics, Diaprost, Diatheva, Dicerna Pharmaceuticals, DiNAQOR, DNA Therapeutics, DNX Biopharmaceuticals, Dogma Therapeutics, Domain Therapeutics, Dong-A ST, Dr. Reddy's Laboratories, Dragonfly Therapeutics, DreaMed Diabetes, DSM, Dual Therapeutics, Duke-NUS Graduate Medical School Singapore, Duke University, Dynacure, Eagle Pharmaceuticals, Eddingpharm, Edelris, Editas Medicine, Educational and Scientific, Eirion Therapeutics, Eisai, Elanco, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, EMD Millipore, EMD Serono, Emergent BioSolutions, Emergex Vaccines, Emory University, Emulate, Endotherm, Enochian Biosciences, Ensysce Biosciences, Entasis Therapeutics, Enterome Bioscience, Entia Biosciences, Enumeral Biomedical, Environmental Protection Agency, ENYO Pharma, Epigen Biosciences, Epilepsy Foundation (EF), EpimAb Biotherapeutics, Erytech, Escient Pharmaceuticals, EspeRare Foundation, Essex Bio-Technology, Esteve, Eternygen, Ethris, Euclises Pharmaceuticals, Eureka Eurostars, Eureka Therapeutic, Eurofins Discovery, European Union, Evecxia, Everest Medicines, Evolva, Evotec, ExCellThera, Excelra, Exelixis, Exicure, Exonate, Expesicor, EyeMedics, Eyevance, F1 Oncology, FAAH Pharma, Facit, Fapon Biopharma, Fast Forward, Fatro, Federal Ministry of Education and Research (BMBF), Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, FerGene, Ferring Pharmaceuticals, Fibriant, Fibrocell Science, Fibrocor Therapeutics, Fimbrion Therapeutics, Five Prime Therapeutics, Flemish agency for Innovation by Science and Technology, Flexion Therapeutics, FloDesign Sonics, Florey Institute of Neuroscience and Mental Heath, Florida International University, Florida State University, Flowonix, Flow Pharma, FLX Bio, Fondazione Telethon, Forge Therapeutics, FORMA Therapeutics, Formula Pharmaceuticals, Fortify Therapeutics, Fortress Biotech, Forty Seven, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Foundation to Eradicate Duchenne, FoxBio, Fox Chase Cancer Center, Fred Hutchinson Cancer Research Center, Frequency Therapeutics, FSD Pharma, Fudan University, Fuhong Hanlin, Fujifilm, Fulgent Pharma, G-Tech Bio, G1 Therapeutics, G3 Pharmaceuticals, Galapagos, GamaMabs Pharma, Gamida Cell, GB Sciences, Gedeon Richter, Gem Pharma, Gen-Probe, GEn1E Lifesciences, Genea Biocells, GeneCentric Therapeutics, Genentech, GeneQuantum Healthcare, GeneQuine Biotherapeutics, Generex Biotechnology, GeneSegues, Genethon, Genetic Immunity, GeNeuro, Genevant Sciences, Genexine, Genmab, Genomic Health, Genprex, GenScript USA, Gensight, GenSpera, GenStem Therapeutics, Genticel, GenVec, Georgetown University, George Washington University, Georgia State University, GeoVax, German Red Cross, Gesynta Pharma, Gilead Sciences, Glaukos, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Glialogix, Glycotope Biotechnology, Glympse Bio, Glythera, Goldfinch Bio, Government of Australia, Government of Canada, Gradalis, GrayBug, Great Bay Bio, Green Cross LabCell, Grifols, Group K Diagnostics, GTx, Guangzhou Boji Medical Biotechnological, Guangzhou Institute of Biomedicine and Health, Gubra, H&P Labs, Hadasit Medical Research Services and Development, Hadassah Medical Center, Hainan Sihuan Pharmaceutical, HanAll Pharmaceuticals, Hangzhou Zhongmei Huadong Pharmaceutical, HanX Biopharmaceuticals, Harbour Biomed, Harpoon Therapeutics, Harvard University, Hatchtech, Hawaii Biotech, HD Biosciences, Healios K.K., Health Connexions, HemaCare, HemoShear, Henlius Biotech, Henry Ford Health System, Hepion Pharmaceuticals, Heraeus, Hillhurst Biopharmaceuticals, Hillstream BioPharma, Histogenics, HitGen, Hoffmann La Roche, Hologic, Hong Kong Polytechnic University, Hope Medicine, Horizon 2020, Horizon Discovery, Hoth Therapeutics, HSRx Group, Humabs BioMed, Humanetics, Humanigen, Hummingbird Bioscience, Huntsman Cancer Institute, Hybridyne Imaging Technologies, Hydra Biosciences, Hyundai Pharmaceutical, I-Bridge Capital, I-mab, IBC Generium, Ichor Medical Systems, Iconic Therapeutics, iDD Biotech, IDEAYA Biosciences, Idera Pharmaceuticals, Idorsia, IDT Biologika, Igenica, Ignyta, IGXBio, ILiAD Biotechnologies, ImageIQ, ImaginAb, Imago Pharmaceuticals, Imanis Life Sciences, ImCheck Therapeutics, Imcyse, Immodulon Therapeutics, ImmuNext, Immunic, ImmunoBiochem, Immunocore, ImmunoForge, ImmunoGen, Immunomedics, Immunomic, ImmunoPhotonics, ImmunoQure, Imperial College London, Imperial Innovations, Inception Sciences, Incyte, Indiana University, Indica Labs, Indivior, Inexia, Infectious Disease Research Institute (IDRI), Infinity Pharmaceuticals, InflamaCORE, Inflection Biosciences, Inhibikase Therapeutics, Inhibrx, Initiator Pharma, INmune Bio, Innate Pharma, Innovate Biopharmaceuticals, Innovate UK, Innovent Biologics, Inoviem Scientific, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Insilico, Insmed Inc, InSphero, Inspyr Therapeutics, Institute for Bioscience and Biotechnology Research, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for the Promotion of Innovation by Science and Technology in Flanders, Institute of Biomedical Research, Institute of Biophysics, Institute of Endocrinology, Metabolism, and Reproduction, Institute of Hematology and Blood Transfusion, Institut Pasteur, Intarcia Therapeutics, IntegraGen, Integrated BioTherapeutics, IntelliCell BioSciences, International Stem Cell, International Vaccine Institute (IVI), Interpace Diagnostics, Intravacc, Intrexon, iNtRON Biotechnology, Invigorcell, Ionis Pharmaceuticals, Io Therapeutics, Iovance Biotherapeutics, IOVaxis Therapeutics, Ipsen, ISA Pharmaceuticals, ISA Scientific, Isomerase Therapeutics, IsoPlexis, Isoprene Pharmaceuticals, Israeli National Authority for Technological Innovation, iTeos Therapeutics, Itus, Iveric Bio, Ivy Brain Tumor Center, Jackson Laboratory, JanOne, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jenner Institute, JHL Biotech, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Qyun Bio-Pharmaceutical, Jiangsu QYuns Therapeutics, John Hopkins University School of Medicines, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, JSC Pharmadis, JSR, Jubilant Biosys, Juno Therapeutics, Just Biotherapeutics, Juvenescence, Juvenile Diabetes Research Foundation, Juventas Therapeutics, JW Pharmaceutical, Kadmon Pharmaceuticals, Kaken Pharmaceutical, Kaldi Pharma, Kalgene Pharmaceuticals, Kalon Biotherapeutics, KalVista Pharmaceuticals, Kalytera Therapeutics, Karo Bio, Karolinska Development, Karolinska Institute, Karus Therapeutics, Karyopharm Therapeutics, Kashiv BioSciences, KBI BioPharma, KDAc Therapeutics, Keio Gijuku University, Kennedy Trust For Rheumatology Research, KineMed, Kineta, Kinetic Concepts, Kinex Pharmaceuticals, Kings College London, Kiniksa Pharmaceuticals, KinoPharma, Kinoxis Therapeutics, Kite Pharma, Knight Cancer Institute, Knight Therapeutics, Knopp Biosciences, Kolltan Pharmaceuticals, KYAN Therapeutics, Kyn Therapeutics, Kyowa Hakko Kirin, Kythera Biopharmaceuticals, L&F Research, L'Oreal, Laboratoires Thea, Laboratory Corporation of America, La Jolla Institute for Allergy & Immunology, La Jolla Pharmaceutical, LambdaVision, Lantern Pharma, Laurel Venture Capital, Lauren Sciences, Lava Therapeutics, Lawson Health Research Institute, LCS Therapeutics, Leap Therapeutics, Lee's Pharmaceutical, Lee Moffitt Cancer Center, Legend Biotech, Leica Biosystems, Leicester University, Leidos, LEITAT, Lentigen, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Leukocare, LGC, LifeArc, LifeMap Sciences, Life Science Research, Ligand Pharmaceuticals, Lightlake Therapeutics, Lin Bioscience, Lineage Cell Therapeutics, LineaRx, Lixte Biotechnology, Locana, Locate Therapeutics, LogicBio Therapeutics, Longevity Biotech, Lonza, Loxo Oncology, LSK BioPharma, LSU Health Sciences Center, Lubeck Institute of Experimental Dermatology, Lucerne Biosciences, Luc Therapeutics, LumiThera, Lundbeck, Lund University, Lung Biotechnology, Lupagen, Lupin Limited, Lupin Pharmaceuticals, Lupus Foundation of America (LFA), Luxcel Biosciences, Lyndra Therapeutics, Lysogene, Lysosomal Therapeutics, Lytix Biopharma, Maastricht University, MabVax Therapeutics, Macrogenics, Mallinckrodt Pharmaceuticals, Mannin Research, MapKure, Mapp Biopharmaceutical, Mars Symbioscience, Maruho, Maryland Stem Cell Research Fund, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Matinas Biopharma, MaveriX Oncology, Max-Planck, Maxcyte, Mayo Clinic, McGill University, McMaster University, MD Anderson Cancer Center, MDA Venture Philanthropy, MDNA Life Sciences, MDxHealth, Medac, Medical Prognosis Institute, Medical Research Council, Medical University of Graz, Medical University of Innsbruck, Medical University of Vienna, Medicenna Therapeutics, Medicines Discovery Catapult, Medifocus, MediGene, MedImmune, Mediolanum, Medison Pharma, Medivir, MediWound, Medtronic, Memorial Sloan Kettering Cancer Center, Menarini, Merck and Co, Merck KGaA, Merck Serono, Merck Sharpe & Dohme, Mersana Therapeutics, Merus, Merz, Mesoblast, Metabasis Therapeutics, Metabolon, Metacrine, Metrion Biosciences, MGB Biopharma, Michael J Fox Foundation, Microbiotica, MicroConstants, MicroCures, Microlin Bio, Midatech, Millar, Millennium, MilliporeSigma, MimiVax, MiNA Therapeutics, Mind Medicine, MinervaX, MiniVax, MirImmune, Mironid, Mission Therapeutics, Mitacs, Mitochon Pharmaceuticals, MITRO Biotech, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Moderna Therapeutics, Modern Biosciences, MolecularMD, Molecular Partners, Molecular Templates, Moleculin Biotech, Molnlycke Health Care, Mologen, Monopar Therapeutics, Moores Cancer Center, MorphoSys, Mount Sinai Medical Center, Mount Tam Biotechnologies, Movember Foundation, MRIGlobal, MultiCell Immunotherapeutics, Multiple Myeloma Research Foundation, Mundipharma, Muscular Dystrophy Association, Mustang Therapeutics, MyBiotics Pharma, Mylan Pharmaceuticals, Mymetics, MYM Nutraceuticals, MyoKardia, Myonexus Therapeutics, MYOS, Naason Science, Naia Pharma, Nancy Lurie Marks Family Foundation, Nanjing BioSciKin, NanoBio, Nanobiotix, Nanotherapeutics, NanoViricides, Nanovis, NantBioScience, NantKwest, Nantong Jinghua Pharmaceutical, NantVentures, NantWorks, Nanyang Technological University, Nascent Biotech, Natera, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Complementary and Integrative Health, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse (NIDA), National Institutes for Quantum and Radiological Science and Technology, National Institutes of Health, National Research Council Industrial Research Assistance Program, National Science Foundation, National Stem Cell Foundation, National University Hospital, National University of Singapore, Nationwide Children’s Hospital, Natural Sciences and Engineering Research Council of Canada, Navidea Biopharmaceuticals, Navitor Pharmaceuticals, NBE Therapeutics, Nektar Therapeutics, Nemucore Medical Innovations, Nencki Institute, Neogenomics, Neomed Institute, Neon Therapeutics, Neos Therapeutics, Neovacs, Nerviano Medical Sciences, Nestle Health Science, Netherlands Cancer Institute, NeurAegis, NeuralStem, Neuraly, NeurAxon, Neurocrine Biosciences, NeuroCycle Therapeutics, Neuron-Experts, NeuroTrauma, NeuroVive Pharmaceutical, NeuRx Pharmaceuticals, Neuway Pharma, Newlink Genetics, New York Blood Center, New York Presbyterian/Columbia, New York University, New Zealand Pharmaceuticals, NEXT Oncology, NGM Biopharmaceuticals, NHS Blood and Transplant, Nicox, Nightstar Therapeutics, Nihon Medi-Physics, Nimbus Therapeutics, Ningbo NewBay Medical Technology, Ningbo Tai Kang Medical Technology, Nitrome Biosciences, NJCTTQ, Noile-Immune Biotech, Nordic Bioscience, North Carolina State University, Northern Biologics, Northern Biomedical Research, NorthShore University HealthSystem, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Norwegian Research Council, Nosopharm, Novan Therapeutics, Novartis, Novartis Institute for Tropical Diseases, NovaSAID, Novigenix, NovImmune, NovoCodex, Novogen, Novonco Pharmaceuticals, Novo Nordisk, Novoron Bioscience, Nuclea Biotechnologies, Nucro Technics, Nuevolution, Numab, Nuo Therapeutics, Nuviant Medical, OBI Pharma, Ocata Therapeutics, Ocular Therapeutics, Ocumension Therapeutics, OcuNexus Therapeutics, Odylia Therapeutics, Ohio State University, OHM Oncology, Ohr Pharmaceuticals, OKYO Pharma, OliX Pharmaceuticals, Ology Bioservices, Oncgnostics, OncoCare Therapeutics, Oncoceutics, Oncodesign, Oncodrone, OncoGenex Pharmaceuticals, OncoImmune, Oncologie, Oncology Venture, Oncolys BioPharma, OncoNano Medicine, Onconova Therapeutics, OncoSec Medical, Oncosynergy, OncoTAb, OncoTracker, OnKure, ONL Therapeutics, Ono Pharmaceutical, Ontario Institute for Cancer Research, Onxeo, Open Monoclonal Technology, Ophirex, Ophthotech, OPKO Health, OptiBiotix, Oragenics, Oraxion Therapeutics, Orca Pharmaceuticals, Orchard Therapeutics, Orexia Therapeutics, Orexo, Organic Vaccines, Organovo, Orgenesis, Oricula Therpeutics, OrImmune Bio, OrthoCyte, Oryzon, OSE Immunotherapeutics, OSI Pharmaceuticals, Ospedale San Raffaele, Ossianix, OS Therapies, Otsuka, Outpost Medicine, OWC Pharmaceutical Research, Oxford BioTherapeutics, Oxis Biotech, Padlock Therapeutics, Paidion Research, Pain Therapeutics, Palatin Technologies, Pall Corporation, Panacea Pharmaceuticals, Pandion Therapeutics, Panion, Panther Biotechnology, Pantherics, PapGene, Paragon Bioservices, Paratek Pharmaceuticals, Parent Project Muscular Dystrophy, Parion Sciences, Paris Descartes University, Parkinson's Institute and Clinical Center, Parkinson's UK, Parnell Pharmaceutical Holdings, Particle Sciences, Parvus Therapeutics, Pascal Biosciences, Passage Bio, PATH (Appropriate Technology in Health), PathMaker Neurosystems, PaxVax, PCI Biotech, PDS Biotechnology, Pediatric Oncology Experimental Therapeutics Investigators Consortium, Pelican Therapeutics, Pep Therapy, Peptide Logic, Perlara, Perrigo, Personal Genome Diagnostics, Petra Pharma, Pfenex, Pfizer, PharmAbcine, Pharmacyclics, PharmaCyte Biotech, PhaseBio Pharmaceuticals, Phico Therapeutics, Phio Pharmaceuticals, Phoenix Molecular Designs, PhoreMost, Phyton Biotech, Pieris, Pierre Fabre, Piramal Imaging, Pixium Vision, PlantArcBio, Plasticell, Plexxikon, Pliant Therapeutics, Pluristem Therapeutics, PoC Capital, Polyphor, Portage Biotech, Poxel, PPD, Prana Biotechnology, Precigen, Precision Biologics, Precision for Medicine, Presage Biosciences, Primary Peptides, Princess Margaret Hospital, Privo Technologies, Probiodrug, ProBioGen, Procarta Biosystems, Procella Therapeutics, Proclara Biosciences, Procyrion, Profectus Biosciences, Progenerative Medical, Progenitor Cell Therapy, Prokaryotics, Prometic Life Sciences, ProNAi Therapeutics, Propeller Health, Prosenex, ProSensa, Prostate Cancer Foundation (PCF), Protagen, Protagonist Therapeutics, Protectimmun, Protein Sciences, Proteostasis Therapeutics, Prothena Biosciences, ProThera, ProtoKinetix, Provecs Medical, Provectus Biopharmaceuticals, Providence Cancer Center, PsiOxus Therapeutics, PTC Therapeutics, Public Health Vaccines, Pulmatrix, Puma Biotechnology, Purdue Pharma, PureTech Health, PvP Biologics, Q BioMed, QED Therapeutics, Qiagen, Qpex Biopharma, QR Pharma, Qualigen, Quartet Medicine, Queensland Institute of Medical Research (QIMR), Quest PharmaTech, Quotient, R-Tech Ueno, Radboud University Nijmegen, Radiomedix, Rafael Pharmaceuticals, Rafa Pharmaceuticals, Rainbow Medical, Rain Therapeutics, Rambam Medical Center, Ramot at Tel Aviv University, Rebiotix, Recombinant Technologies, Recombinetics, Recursion Pharmaceuticals, RedHill Biopharma, Redx Pharma, Regenacy Pharmaceuticals, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regentys, Regenxbio, Regis Technologies, Regulus Therapeutics, Relief Therapeutics, Rempex Pharmaceuticals, reMYND, Reneo Pharmaceuticals, ReNeuron, Renovacare, Renovar, Renova Therapeutics, Renovo, Rentschler Biotechnologie, Repare Therapeutics, Repligen, ReproCell, Research Corporation Technologies, Reset Therapeutics, RESprotect, Restorix Health, Retrotope, RetroVirox, Reveal Biosciences, ReveraGen BioPharma, Revitope, Revolution Medicines, Rexahn Pharmaceuticals, Rexgenero, RH Nanopharmacuticals, Rhythm Pharmaceuticals, Ridgeback Biotherapeutics, Rigel Pharmaceuticals, Riptide Bioscience, Ritter Pharmaceuticals, Robert H. Lurie Comprehensive Cancer Center, Rochal Industries, Roche, Rockefeller University, Rocket Pharmaceuticals, Rockland Immunochemicals, Roivant Sciences, Roswell Park Cancer Institute, Rumpus Therapeutics, RXi Pharmaceuticals, Salix Pharmaceuticals, Sam Chun Dang Pharm, Samsung Bioepis, Samumed, Samyang Biopharmaceuticals, SanBio, Sanford Burnham Institute, Sangamo BioSciences, Saniona, Sanofi, Sanofi-Pasteur, San Raffaele Telethon Institute for Gene Therapy, Santalis Pharmaceuticals, Santen Pharmaceutical, Sapphire Biotech, Sapreme Technologies, Sarepta Therapeutics, Sato Pharmaceutical, Savant HWP, Schrodinger, SciCann Therapeutics, Science for Life Laboratory, Scripps Research Institute, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Second Genome, Seelos Therapeutics, Selecta Biosciences, Selecxine, Selenity Pharmaceuticals, Selexis, SELLAS Life Sciences Group, SeLux Diagnostics, Semma Therapeutics, Seneca Biopharma, SEngine Precision Medicine, Sensei Biotherapeutics, Sensorion, Sensus Healthcare, Sentinel Oncology, Seoul National University, Sequenom, Seraph Research Institute, Serendex Pharmaceuticals, Seres Therapeutics, Sermonix Pharmaceutical, Serum Institute of India, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, Shandong Luoxin Pharma, Shanghai Biotechnology, Shanghai Cancer Institute, ShangPharma, Shanxi Yabao Pharmaceutical Distribution, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Shenzhen Salubris Pharmaceuticals, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shin Nippon Biomedical Laboratories, Shionogi, Shire Laboratories, Shire Pharmaceuticals, SIGA Technologies, Sigilon Therapeutics, SignPath Pharmaceuticals, Signum Biosciences, Signum Dermalogix, Silence Therapeutics, Simcere Pharmaceuticals, Sino Biopharmaceutical, SinSa Labs, Sirenas, Sirona Biochem, Skolkovo Foundation, SKS Ocular, Small Business Innovation Research, Smartwise, Solarvest BioEnergy, Solid Biosciences, Soligenix, Somanetics, Sonnet BioTherapeutics, Sorrento Therapeutics, Sosei, Sosei Heptares, SOTIO, Sourasky Medical Center, Sourcia, Southern Research Institute, Spark Therapeutics, Spero Therapeutics, Spherix, Spiral Genetics, Spiral Therapeutics, Spotlight Innovation, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, SQZ Biotech, SRI International, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Starpharma, Staten Biotechnology, StemCell Systems, Stem Cell Theranostics, Stemina Biomarker Discovery, Stemline Therapeutics, Stony Brook University, Structural Genomics Consortium, St Vincent’s Institute of Medical Research, Summit Therapeutics, Sunesis Pharmaceuticals, Sunnybrook Research Institute, SunTerra Biotechnology, Surface Oncology, SurModics, SutroVax, Suzhou NeuPharma, Swedish Orphan, Swedish Orphan Biovitrum, Swedish Research Council, Swiss Biotech Center, Symbiotix Biotherapies, Symcel, Symic Biomedical, Synaffix, Syndax Pharmaceuticals, Syndesi Therapeutics, Synergys Biotherapeutics, Syngene, Synovo, Synpromics, Synthetic Genomics, Synthon, T3 Labs, Tactiva Therapeutics, Taiho, Taipei Medical University, TaiRx, Takeda America Holdings, Takeda Pharmaceutical, Talee Bio, Talix Therapeutics, Tamid Bio, Tampere University Hospital, Targacept, Targovax, Tarsius Pharma, Tasly Pharmaceuticals, Tavotek Biotherapeutics, TAXIS Pharmaceuticals, Taxus Pharmaceuticals, TB Alliance, TC BioPharm, Technion Research and Development Foundation, Technology Strategy Board (UK), TechnoVax, Teijin, Tekmira Pharmaceuticals, Tel Aviv University, Telik, Telix Pharmaceuticals, Telo Genomics, TeneoBio, TeneoOne, Terns Pharmaceuticals, Tesaro, Tessa Therapeutics, Tetra Bio-Pharma, Tetragenetics, TetraLogic Pharmaceuticals, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Texas Biomedical Research Institute, TG Therapeutics, The Alpha-1 Project, The Cure Parkinson's Trust, The HUB Foundation, The International AIDS Vaccine Initiative, The Parker Institute For Cancer Immunotherapy, TheraBiologics, Theragnostics, Theralase, Therapeutic Solutions International, Therapix Bio, Theravance Biopharma, TheraVasc, Theravectys, The Regents of the University of California, Thermalin Diabetes, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Threshold Pharmaceuticals, ThromboGenics, Tiburio Therapeutics, Tikcro Technologies, Tillotts Pharma, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TNK Therapeutics, Tobira Therapeutics, TONIX Pharmaceuticals, Torii Pharmaceutical, TOT BIOPHARM, Toulouse University Hospital, TRACON Pharmaceuticals, Traffick Therapeutics, TransBio, Transgene, Transgene Tasly Biopharmaceutical, Transimmune, Translational Genomics Research Institute, TransTech Pharma, Traverse Biosciences, Treeway, Trefoil Therapeutics, Trellis Bioscience, Trethera, Trieza Therapeutics, TRIGR Therapeutics, Triphase Accelerator, Triumvira Immunologics, TrojanTec, TrovaGene, TSRL, Tufts Medical Center, Tufts University, Turgut Ilaclari, Turing Pharmaceuticals, Turnstone Biologics, TxCell, UAB Research Foundation, Ubiquigent, UCB, Ultragenyx Pharmaceuticals, UMass Memorial Medical Center, Unilever, UniQure, United Therapeutics, UNITY Biotechnology, Universal Cells, Universite catholique de Louvain, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of Bergen, University of Birmingham, University of Bristol, University of British Columbia, University of California, San Diego, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Cincinnati, University of Cologne, University of Colorado Denver, University of Connecticut, University of Copenhagen, University of Exeter, University of Florida Research Foundation, University of Guelph, University of Hawaii, University of Helsinki, University of Kentucky, University of Leuven, University of Liverpool, University of Louisville, University of Lyon, University of Maryland Baltimore, University of Massachusetts, University of Massachusetts, Amherst, University of Massachusetts Medical School, University of Melbourne, University of Michigan, University of Minnesota, University of Missouri, University of Montreal, University of Munster, University of Nagasaki, University of Nebraska, University of New Mexico, University of New South Wales, University of North Carolina, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Reading, University of Rochester, University of Saskatchewan, University of Sheffield, University of Sherbrooke, University of Surrey, University of Tennessee, University of Texas, University of Tokyo, University of Toledo, University of Toronto, University of Virginia, University of Washington, University of Wisconsin, University of Wisconsin-Madison, Uppsala University, UroGen Pharma, US Army, US Army Institute of Surgical Research (USAISR), US Army Medical Research Institute of Infectious Diseases, US Medical Innovations, US Oncology Research, Valbiotis, Valeant Pharmaceuticals, Validogen, Valo Therapeutics, Van Andel Research Institute, Vanda Pharmaceuticals, Vanderbilt University, Variant Pharmaceuticals, Vault Pharma, Vaxess Technologies, Vaxil BioTherapeutics, Vaximm, VBI Vaccines, VDM Biochemicals, Vectura, Vedanta Biosciences, Velesco, VenatoRx, Ventana Medical Systems, Venus Medtech, Verastem, Vernalis, Versant Ventures, Verseau Therapeutics, Vertex Pharmaceuticals, ViaCyte, Viamet Pharmaceuticals, ViaMune, Viatar CTC Solutions, Vical, Viela Bio, Vigilant Biosciences, ViiV Healthcare, Viking Therapeutics, Vineti, Vinnova, Viracta Therapeutics, ViraTherapeutics, Vir Biotechnology, Virginia Catalyst, Viroclinics Biosciences, Viscogliosi Brothers, Visterra, Vitae Pharmaceuticals, Vital Therapies, Viteava Pharmaceuticals, Viva Biotech, Vivaldi Biosciences, ViveBio, Vivet Therapeutics, Vivoryon Therapeutics, VLP Therapeutics, Vor Biopharma, vTv Therapeutics, VU Medical Center, Vyriad, Wallace H. Coulter Foundation, Walter and Eliza Hall Institute, Wanbang Biopharmaceuticals, Washington State University, Washington University in St Louis, WCTE, Weill Cornell Medical College, Wellcome Trust, Western Oncolytics, Windtree Therapeutics, Winthrop-University Hospital, Wistar Institute, Wize Pharma, W L Gore, Woodland Biosciences, Worldwide Clinical Trials, WPD Pharmaceuticals, Wuxi Apptec Laboratory Services, WuXi Biologics, WuXi PharmaTech, X-chem, X4 Pharmaceuticals, Xencor, Xenon Pharmaceuticals, Xention, XL-Protein, Xoma, Xonovo, XTL Biopharmaceuticals, Xynomic Pharmaceuticals, Y-Biologics, Y-Trap, Yabao Pharmaceutical, Yale University, Yeda Research and Development Company, Yisheng Biopharma, Yissum Research Development, Yonsei University Severance Hospital, Yuhan Corporation, ZAI Laboratory, ZappRx, Zealand Pharma, Zelluna Immunotherapy, Zhejiang Bossan Pharmaceutical, Zhejiang Haichang Biotechnology, Zhejiang Hisun Pharmaceutical, Zhittya Genesis Medicine, Ziopharm Oncology, Zoetis, Zylo Therapeutics, Zymeworks, ZYUS Life Sciences, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.